Research notice: This page summarizes investigational research for scientific and educational purposes only. The cell-based products discussed are investigational, are not approved by the U.S. FDA, and have not been shown to be safe or effective for any disease or condition. Results from early-stage or retrospective studies are preliminary and are not claims about any BHI product. This is not medical advice.
Note: The following references or summarizes published, peer-reviewed scientific literature and is provided for educational and informational purposes only. It is not a claim that any product is safe or effective, has not been evaluated by the FDA, and is not medical advice. Our cellular and exosome products are investigational and are not FDA-approved.
CellR4 2018; 6 (2): e2521
Allogeneic umbilical cord blood mononuclear cell therapy for spinal cord injury – a retrospective cohort study
Mehling B. M. , Wu D. C. , Quartararo L. , Roman S. J. , Pickoff A. S. , Stolfi A. , Szelestey B. , Rutherford R. , Manvelyan M.
Topic: Stem cells Category: Original Articles
Abstract
OBJECTIVE: Previous studies have reported that human umbilical cord blood-derived stem cell therapy has been studied in subjects with Spinal Cord Injury (SCI). The objective of this retrospective cohort study was to analyze the muscle, nerve, urinary, and gastrointestinal function in subjects with SCI, treated with either human umbilical cord blood-derived mononuclear cells (hUCMNCs) or conventional therapy.
PATIENTS AND METHODS: Thirty subjects with SCI were randomly selected from seventy treated with hUCMNCs therapy in the Wuhan Hongqiao Brain Hospital Co., Ltd. (Wuhan, Hubei) between March 2009 and March 2012. Another thirty subjects with SCI, received only conventional therapy and no hUCMNCs therapy, were included as the control group.
RESULTS: Uncultured hUCMNCs were used for therapy of subjects with SCI. No subjects developed adverse reactions, further demonstrating the safety of hUCMNCs therapy. A significantly higher proportion of subjects in the hUCMNCs therapy group showed improved function in pain and temperature sensation, lower limb muscle strength, bladder function, and gastrointestinal function compared to a conventional therapy group.
CONCLUSIONS: Application of hUCMNCs was effective in the therapy of subjects with SCI. In order to further analyze the safety and efficacy of hUCMNCs therapy for SCI subjects, further prospective studies are warranted.
Free PDF Download
To cite this article
Mehling B. M. , Wu D. C. , Quartararo L. , Roman S. J. , Pickoff A. S. , Stolfi A. , Szelestey B. , Rutherford R. , Manvelyan M.
Allogeneic umbilical cord blood mononuclear cell therapy for spinal cord injury – a retrospective cohort study
CellR4 2018; 6 (2): e2521
Publication History
Submission date: 28 Mar 2018
Revised on: 09 Apr 2018
Accepted on: 25 May 2018
Published online: 25 Jun 2018